What Are Tumour Markers?
Tumour markers are substances, often proteins, that can be found in the blood, urine, or body tissues. They are produced either by the body in response to certain conditions or by specific types of cells themselves. While they are sometimes associated with the presence of cancer, it is crucial to understand that elevated levels of tumour markers do not necessarily mean cancer is present. Many non-cancerous conditions can also cause these levels to rise. [1]
As highlighted by Cancer Research UK, tumour markers are usually proteins that can be measured through a simple blood test. [2] They are one piece of a larger puzzle and are most effectively used alongside other clinical information and diagnostic tools.
Key Tumour Markers in Women’s Health
Several specific tumour markers are particularly relevant to women’s health. Understanding these can help demystify the terminology often used in medical settings.
- CA125: This is perhaps the most well-known tumour marker associated with women’s health. It is often used in the assessment of ovarian cysts and pelvic masses. However, the National Institute for Health and Care Excellence (NICE) notes that CA125 can also be elevated in benign conditions such as endometriosis, fibroids, and even during menstruation. [3] Therefore, it is a tool for gathering information rather than a definitive diagnostic test on its own.
- CA 15-3: This marker is primarily associated with breast health. While it is not typically used for initial screening, it can provide useful information when monitored over time in specific clinical scenarios. [4]
- Beta-hCG: Human chorionic gonadotropin (hCG) is widely known as the hormone detected in pregnancy tests. However, in certain contexts outside of pregnancy, elevated levels can act as a tumour marker for specific types of conditions, including some ovarian germ cell tumours. [5]
The Role of Tumour Markers in Proactive Health
The primary value of understanding your tumour marker levels lies in the broader context of proactive health management. These markers can help provide insight into your body’s current state. They are not diagnostic guarantees, but rather indicators that may prompt further investigation or provide a baseline for future monitoring.
For instance, if a woman has a family history of certain conditions, monitoring specific markers might be part of a comprehensive health strategy discussed with her doctor. It is about moving from a reactive stance—waiting for symptoms to appear—to a proactive one, where you are actively engaged in understanding your health profile.
Empowering Your Health Journey with Clinilabs
Taking control of your health journey involves having access to the right information at the right time. The Tumour Markers (Female) Blood Test from Clinilabs is designed to provide you with a detailed analysis of key markers relevant to women’s health. This comprehensive test can form part of a proactive approach, offering insights that may support informed conversations with a healthcare professional.
By choosing to understand your unique biomarker profile, you are taking an empowering step towards proactive health management. It is about gaining knowledge, reducing uncertainty, and making informed decisions about your wellbeing.
Explore this topic
Continue reading the related articles in this series:
- Early detection: Demystifying CA125
- Personalised insights: What is CA 15-3?
- Empowerment: Beta-hCG as a Tumour Marker
Related test: Tumour Markers (Female) Blood Test at Clinilabs.
References
[1] Cancer Research UK. (n.d.). Tests for cancer of unknown primary (CUP). https://www.cancerresearchuk.org/about-cancer/cancer-unknown-primary-cup/getting-diagnosed/tests-cancer-unknown-primary-cup
[2] Cancer Research UK. (n.d.). Tests for breast cancer. https://www.cancerresearchuk.org/about-cancer/breast-cancer/getting-diagnosed/tests
[3] National Institute for Health and Care Excellence (NICE). (2011). Ovarian cancer: recognition and initial management. https://www.nice.org.uk/guidance/cg122
[4] Gloucestershire Hospitals NHS Foundation Trust. (n.d.). CA 15-3 (Tumour marker). https://www.gloshospitals.nhs.uk/our-services/services-we-offer/pathology/tests-and-investigations/ca-15-3-tumour-marker/
[5] Imperial College Healthcare NHS Trust. (n.d.). Ovarian germ cell cancer. https://www.imperial.nhs.uk/-/media/website/patient-information-leaflets/cancer-services/gestational-trophoblastic-disease/ovarian-germ-cell-cancer.pdf